SomnoMedASX:SOM -1.87%51 OCF Yield % is 6.70 as of Jun. 29, 2026. GuruFocus rates ASX:SOM with a GF Score™ of 51/100 and a GF Value™ of A$0.45 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 851 Medical Devices & Instruments companies, SomnoMed ranks better than 74.62% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for SomnoMed's OCF Yield % or its related term are showing as below:
ASX:SOM'
s OCF Yield % Range Over the Past 10 Years
Min: -20.57 Med: -1.28 Max: 7
Current: 6.7
During the past 13 years, the highest OCF Yield % of SomnoMed was 7.00%. The lowest was -20.57%. And the median was -1.28%.
ASX:SOM's OCF Yield % is ranked better than 74.62% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 1.76
vs ASX:SOM: 6.70
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
SomnoMed OCF Yield % Related Terms
SomnoMed OCF Yield % Historical Data
* Premium members only.
The historical data trend for SomnoMed's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SomnoMed's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's OCF Yield % distribution charts can be found below:
* The bar in red indicates where SomnoMed's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (ASX:SOM) has a OCF Yield % of 6.70 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on SomnoMed and its competitors. According to the industry distribution chart, SomnoMed ranks #216 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 25.4%.
Is SomnoMed's OCF Yield % too high?
SomnoMed's current OCF Yield % is 6.70. The Medical Devices & Instruments industry median OCF Yield % is 1.76. SomnoMed's value of 6.70 is 280.7% above this industry median. Based on the distribution chart, SomnoMed ranks #216 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SomnoMed has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #216 out of 851 companies for OCF Yield %. This puts SomnoMed in the upper half of its industry. The industry median OCF Yield % is 1.76. SomnoMed's value of 6.70 is 280.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.76, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SomnoMed's current OCF Yield % of 6.70 is 280.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on SomnoMed and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current OCF Yield % is 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.53 — trading 16.7% above its estimated fair value. The current OCF Yield % is 6.70 and 280.7% above the Medical Devices & Instruments industry median of 1.76. SomnoMed's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current OCF Yield % is 6.70 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (ASX:SOM) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of A$0.53 is trading 16.7% above its estimated GF Value™ of A$0.45.
GuruFocus considers SomnoMed to be Modestly Overvalued.
Key valuation signals for ASX:SOM:
OCF Yield %: 6.70
GF Value™: A$0.45 vs. price of A$0.53 (16.7% above fair value)
Industry Position: 280.7% above the Medical Devices & Instruments median (#216 of 851)
No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
51GF Score
Get the complete analysis for ASX:SOM
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SOM has been successfully added to your 
